Rizzo M - Search Results

1

A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.

Vekic J, Zeljkovic A, Al Rasadi K, Cesur M, Silva-Nunes J, Stoian AP, Rizzo M. Vekic J, et al. Among authors: rizzo m. Metabolites. 2022 Jan 24;12(2):108. doi: 10.3390/metabo12020108. Metabolites. 2022. PMID: 35208183 Free PMC article. Review.

2

Atherogenic dyslipidemia and oxidative stress: a new look.

Rizzo M, Kotur-Stevuljevic J, Berneis K, Spinas G, Rini GB, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Vekic J. Rizzo M, et al. Transl Res. 2009 May;153(5):217-23. doi: 10.1016/j.trsl.2009.01.008. Epub 2009 Feb 23. Transl Res. 2009. PMID: 19375682 Review.

3

Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis.

Rizzo M, Spinas GA, Cesur M, Ozbalkan Z, Rini GB, Berneis K. Rizzo M, et al. Atherosclerosis. 2009 Dec;207(2):502-6. doi: 10.1016/j.atherosclerosis.2009.07.015. Epub 2009 Jul 8. Atherosclerosis. 2009. PMID: 19643412

4

Should we routinely measure low-density and high-density lipoprotein subclasses?

Rizzo M, Berneis K, Zeljkovic A, Vekic J. Rizzo M, et al. Clin Lab. 2009;55(11-12):421-9. Clin Lab. 2009. PMID: 20225664

5

An update on the relationships between rheumatoid arthritis and atherosclerosis.

Ozbalkan Z, Efe C, Cesur M, Ertek S, Nasiroglu N, Berneis K, Rizzo M. Ozbalkan Z, et al. Among authors: rizzo m. Atherosclerosis. 2010 Oct;212(2):377-82. doi: 10.1016/j.atherosclerosis.2010.03.035. Epub 2010 Apr 4. Atherosclerosis. 2010. PMID: 20430394 Review.

6

Effects of rosiglitazone on fasting and postprandial low- and high-density lipoproteins size and subclasses in type 2 diabetes.

Rizzo M, Vekic J, Koulouris S, Zeljkovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Rini GB, Sakellariou D, Pastromas S, Mikhailidis DP, Manolis AS. Rizzo M, et al. Angiology. 2010 Aug;61(6):584-90. doi: 10.1177/0003319710366431. Epub 2010 May 12. Angiology. 2010. PMID: 20462890

7

Prevalence of dyslipidemia and associated risk factors in Turkish adults.

Bayram F, Kocer D, Gundogan K, Kaya A, Demir O, Coskun R, Sabuncu T, Karaman A, Cesur M, Rizzo M, Toth PP, Gedik V. Bayram F, et al. Among authors: rizzo m. J Clin Lipidol. 2014 Mar-Apr;8(2):206-16. doi: 10.1016/j.jacl.2013.12.011. Epub 2014 Jan 19. J Clin Lipidol. 2014. PMID: 24636181

8

Treatment options for managing atherogenic dyslipidemia and fatty liver disease.

Rizzo M, Montalto G, Al-Rasadi K. Rizzo M, et al. Expert Opin Pharmacother. 2014 Jun;15(8):1065-8. doi: 10.1517/14656566.2014.902051. Epub 2014 Mar 27. Expert Opin Pharmacother. 2014. PMID: 24673432

9

The effects of anti-diabetic drugs on LDL subclasses: any role for colesevelam?

Rizzo M, Mikhailidis DP, Al-Rasadi K. Rizzo M, et al. Cardiovasc Drugs Ther. 2014 Jun;28(3):205-7. doi: 10.1007/s10557-014-6521-1. Cardiovasc Drugs Ther. 2014. PMID: 24867816 No abstract available.

10

Nutraceuticals in lipid-lowering treatment: a narrative review on the role of chitosan.

Patti AM, Katsiki N, Nikolic D, Al-Rasadi K, Rizzo M. Patti AM, et al. Among authors: rizzo m. Angiology. 2015 May;66(5):416-21. doi: 10.1177/0003319714542999. Epub 2014 Jul 18. Angiology. 2015. PMID: 25037700 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,301 results

Search Page